Next-generation therapy for residual prostate cancer

Immunotherapy

Volumn 5, Issue 11, 2013, Pages 1235-1241

  Clarke, Raymond A ^a   Allen, Barry J ^a  

^a UNIVERSITY OF WESTERN SYDNEY   (Australia)

Author keywords

therapy; actinium; adjuvant therapy; alpharadin; bismuth; prostate cancer therapy; PSMA; radioimmunotherapy; TAT

Indexed keywords

ABIRATERONE; BISMUTH 213; DEFEROXAMINE; DOCETAXEL; ENZALUTAMIDE; FLUORODEOXYGLUCOSE F 18; MONOCLONAL ANTIBODY J591; MUCIN 1; PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROSTATE STEM CELL ANTIGEN; RADIOISOTOPE; RADIUM CHLORIDE RA 223; TRACER; UNCLASSIFIED DRUG; ZIRCONIUM 89;

ADVANCED CANCER; ANDROGEN DEPRIVATION THERAPY; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER GROWTH; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CANCER THERAPY; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL EFFECTIVENESS; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DRUG EFFICACY; DRUG HALF LIFE; HUMAN; IMMUNOREACTIVITY; ISOTOPE LABELING; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS FREE SURVIVAL; METASTATIC MELANOMA; MINIMAL RESIDUAL DISEASE; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIOIMMUNOTHERAPY; REVIEW; TARGETED ALPHA IMMUNOTHERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; XENOGRAFT;

ANDROGEN ANTAGONISTS; ANDROGENS; CASTRATION; CHEMOTHERAPY, ADJUVANT; HUMANS; MALE; NEOPLASM, RESIDUAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS;

EID: 84887258430     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt.13.127     Document Type: Review

References (46)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J. Clin. 61(2), 69-90 (2011).
2. Klotz L, Zhang L, Lam A, Nam R, Mamedov A, Loblaw A. Clinical results of long-term follow-up of a large, active surveillance cohort with localized prostate cancer. J. Clin. Oncol. 28(1), 126-131 (2010).
3. Eggener SE, Scardino PT, Walsh PC et al. Predicting 15-year prostate cancer specifc mortality after radical prostatectomy. J. Urol. 185(3), 869-875 (2011).
4. Bill-Axelson A, Holmberg L, Ruutu M et al. Radical prostatectomy versus watchful waiting in early prostate cancer. N. Engl. J. Med. 364(18), 1708-1717 (2011).
5. Zelefsky MJ, Reuter VE, Fuks Z, Scardino P, Shippy A. Infuence of local tumor control on distant metastases and cancer related mortality after external beam radiotherapy for prostate cancer. J. Urol. 179(4), 1368-1373; discussion 1373 (2008).
6. Kuban DA, Tucker SL, Dong L et al. Long-term results of the m. D. Anderson randomized dose-escalation trial for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 70(1), 67-74 (2008). (Pubitemid 350251041)
7. Scher HI, Fizazi K, Saad F et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N. Engl. J. Med. 367(13), 1187-1197 (2012).
8. Hortobagyi GN. Overview of treatment results with trastuzumab (herceptin) in metastatic breast cancer. Semin. Oncol. 28(6 Suppl. 18), 43-47 (2001). (Pubitemid 34062048)
9. Allen BJ. Future prospects for targeted alpha therapy. Curr. Radiopharm. 4(4), 336-342 (2011).
10. Kang HJ, Lee SS, Byun BH et al. Repeated radioimmunotherapy with (131)I-rituximab for patients with low-grade and aggressive relapsed or refractory B cell non-hodgkin lymphoma. Cancer Chemother. Pharmacol. 71(4), 945-953 (2013).
11. Jurcic JG, Larson SM, Sgouros G et al. Targeted alpha particle immunotherapy for myeloid leukemia. Blood 100(4), 1233-1239 (2002). (Pubitemid 34864277)
12. Allen BJ, Raja C, Rizvi S et al. Intralesional targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 4(12), 1318-1324 (2005). (Pubitemid 43131174)
13. Allen BJ, Singla AA, Rizvi Sm et al. Analysis of patient survival in a Phase I trial of systemic targeted alpha-therapy for metastatic melanoma. Immunotherapy 3(9), 1041-1050 (2011).
14. Raja C, Graham P, Abbas Rizvi SM et al. Interim ana lysis of toxicity and response in Phase 1 trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol. Ther. 6(6), 846-852 (2007) (Pubitemid 351574972)
15. Tagawa S T, Beltran H, Vallabhajosula S et al. Anti-prostate-specifc membrane antigen-based radioimmunotherapy for prostate cancer. Cancer 116(Suppl. 4), 1075-1083 (2010).
16. Akhtar NH, Pail O, Saran A, Tyrell L, Tagawa ST. Prostate-specifc membrane antigen-based therapeutics. Adv. Urol. 2012, 973820 (2012).
17. Seidl C, Zockler C, Beck R, Quintanilla-Martinez L, Bruchertseifer F, Senekowitsch-Schmidtke R. Lu-177-immunotherapy of experimental peritoneal carcinomatosis shows comparable effectiveness to Bi-213-immunotherapy, but causes toxicity not observed with Bi-213. Eur. J. Nucl. Med. Mol. I 38(2), 312-322 (2011).
18. Rizvi Sma, Henniker AJ, Goozee G, Allen BJ. In vitro testing of the leukaemia monoclonal antibody wm-53 labeled with alpha and beta emitting radioisotopes. Leukemia Res. 26(1), 37-43 (2002). (Pubitemid 33081089)
19. Bloomer WD, Mclaughlin WH, Lambrecht RM et al. At-211 radiocolloid therapy: further observations and comparison with radiocolloids of p-32, dy-165, and y-90. Int. J. Radiat. Oncol. 10(3), 341-348 (1984). (Pubitemid 14110167)
20. Huang CY, Oborn BM, Guatelli S, Allen BJ. Monte carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy. Med. Phys. 39(3), 1282-1288 (2012).
21. Allen BJ. Can alpha-radioimmunotherapy increase effcacy for the systemic control of cancer? Immunotherapy 3(4), 455-458 (2011).
22. Abbas N, Heyerdahl H, Bruland OS, Borrebaek J, Nesland J, Dahle J. Experimental alpha-particle radioimmunotherapy of breast cancer using 227th-labeled p-benzyl-dota-trastuzumab. EJNMMI Res. 1(1), 18 (2011).
23. Wild D, Frischknecht M, Zhang H et al. Alpha-versus beta-particle radiopeptide therapy in a human prostate cancer model (213bi-DOTA-pesin and 213bi-AMBA versus 177lu-DOTA-pesin). Cancer Res. 71(3), 1009-1018 (2011).
24. 213Bi labeled multiple targeted alpha radioimmunoconjugates. Clin. Cancer Res. 15(3), 865-875 (2009).
25. Apostolidis C, Molinet R, Rasmussen G, Morgenstern A. Production of Ac-225 from Th-229 for targeted alpha therapy. Anal. Chem. 77(19), 6288-6291 (2005). (Pubitemid 41436964)
26. Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specifc membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82(11), 2256-2261 (1998). (Pubitemid 28240834)
27. Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specifc membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol. Oncol. Res. 15(2), 167-172 (2009).
28. Ananias HJ, Van Den Heuvel MC, Helfrich W, De Jong IJ. Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specifc membrane antigen in lymph node and bone metastases of prostate cancer. Prostate 69(10), 1101-1108 (2009).
29. Israeli RS, Powell C T, Fair WR, Heston WD. Molecular cloning of a complementary DNA encoding a prostate-specifc membrane antigen. Cancer Res. 53(2), 227-230 (1993). (Pubitemid 23031827)
30. Israeli RS, Powell C T, Corr JG, Fair WR, Heston Wd: Expression of the prostate-specifc membrane antigen. Cancer Res. 54(7), 1807-1811 (1994).
31. Wright GL Jr, Grob BM, Haley C et al. Upregulation of prostate-specifc membrane antigen after androgen-deprivation therapy. Urology 48(2), 326-334 (1996). (Pubitemid 26279634)
32. Sweat SD, Pacelli A, Murphy G P, Bostwick DG. Prostate-specifc membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology 52(4), 637-640 (1998). (Pubitemid 28440171)
33. Troyer JK, Beckett ML, Wright GL Jr. Detection and characterization of the prostate-specifc membrane antigen (psma) in tissue extracts and body fuids. Int. J. Cancer 62(5), 552-558 (1995).
34. Sokoloff RL, Norton KC, Gasior CL, Marker KM, Grauer LS. A dual-monoclonal sandwich assay for prostate-specifc membrane antigen: levels in tissues, seminal fuid and urine. Prostate 43 (2), 150-157 (2000). (Pubitemid 30220618)
35. Chang SS, Reuter VE, Heston WD, Bander NH, Grauer LS, Gaudin PP. Five different anti-prostate-specifc membrane antigen (psma) antibodies confrm psma expression in tumor-associated neovasculature. Cancer Res. 59(13), 3192-3198 (1999). (Pubitemid 29316022)
36. Allen BJ, Raja C, Rizvi S, Song EY, Graham P. T umour anti-vascular alpha therapy: a mechanism for the regression of solid tumours in metastatic cancer. Phys. Med. Biol. 52(13), L15-L19 (2007). (Pubitemid 46908610)
37. Bander NH, Nanus DM, Milowsky MI, Kostakoglu L, Vallabahajosula S, Goldsmith SJ: Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specifc membrane antigen. Semin. Oncol. 30(5), 667-676 (2003).
38. Liu H, Moy P, Kim S et al. Monoclonal antibodies to the extracellular domain of prostate-specifc membrane antigen also react with tumor vascular endothelium. Cancer Res. 57(17), 3629-3634 (1997). (Pubitemid 27381196)
39. Liu H, Rajasekaran AK, Moy P et al. Constitutive and antibody-induced internalization of prostate-specifc membrane antigen. Cancer Res. 58(18), 4055-4060 (1998). (Pubitemid 28440554)
40. Abbas Rizvi SM, Song EY, Raja C et al. Preparation and testing of bevacizumab radioimmunoconjugates with bismuth-213 and bismuth-205/bismuth-206. Cancer Biol. Ther. 7(10), 1547-1554 (2008).
41. Allen BJ. Clinical trials of targeted alpha therapy for cancer. Rev. Recent Clin. Trials 3(3), 185-191 (2008).
42. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted alpha therapy of human prostate cancer with bi-213 labeled j591 antibody against the prostate specifc membrane antigen. Prostate Cancer Prostatic Dis. 5(1), 36-46 (2002). (Pubitemid 34257306)
43. Holland J P, Divilov V, Bander NH, Smith-Jones PM, Larson SM, Lewis JS. Zr-89-dfo-j591 for immuno-PET of prostate-specifc membrane antigen expression in vivo. J. Nucl. Med. 51(8), 1293-1300 (2010).
44. Holland J P, Sheh Y, Lewis JS. Standardized methods for the production of high specifc-activity zirconium-89. Nucl. Med. Biol. 36(7), 729-739 (2009).
45. Anderson CJ, Schwarz S W, Connett JM et al. Preparation, biodistribution and dosimetry of copper-64-labeled anti-colorectal carcinoma monoclonal antibody fragments 1a3-f(ab')2. J. Nucl. Med. 36(5), 850-858 (1995).
46. Lindmo T, Boven E, Cuttitta F, Fedorko J, Bunn PA Jr. Determination of the immunoreactive fraction of radiolabeled monoclonal antibodies by linear extrapolation to binding at infnite antigen excess. J. Immunol. Methods 72(1), 77-89 (1984). (Pubitemid 14091996)